Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab for Chronic Spontaneous Urticaria (Phase 2b, Greece)
2020-002759-39Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tezepelumab in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Amgen. Primary endpoint: Change from baseline in UAS7 at week 16. Started Mar 2021; status: completed.
02
Drugs
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2020-002759-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002759-39.